查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950465

遺傳性血管性水腫 (HAE) 治療市場按適應症、藥物類別、給藥途徑、分銷管道和患者年齡層分類，全球預測，2026-2032 年

Drugs for HAE Market by Indication Type, Drug Class, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，遺傳性血管性水腫 (HAE) 治療市場價值將達到 37.5 億美元，到 2026 年將成長至 42.9 億美元，到 2032 年將達到 84.2 億美元，複合年成長率為 12.24%。

關鍵市場統計數據
基準年 2025 37.5億美元
預計年份：2026年 42.9億美元
預測年份 2032 84.2億美元
複合年成長率 (%) 12.24%

這是一份簡明的臨床和治療指南，概述了遺傳性血管性水腫的病理生理學、治療類別以及不斷變化的患者照護重點。

遺傳性血管性水腫（HAE）是一種罕見的遺傳性疾病，其特徵是陣發性、非搔癢性腫脹，由激肽釋放酶-激肽系統失調和血管活性肽緩激肽過度生成引起。臨床上，它表現為不可預測的發作，涉及四肢、臉部、呼吸道和胃腸道，既可導致危及生命的急性病症，也可造成慢性生活品質負擔。其病理生理機轉主要集中在C1酯酶抑制劑的數量或功能缺陷，或激肽釋放酶活性調節成分的特定缺陷，這些因素共同促進緩激肽介導的血管滲透性增加。

科學創新、不斷發展的醫療服務模式以及支付方對實際療效的關注，正在如何重塑遺傳性血管性水腫的治療方案和診療路徑？

遺傳性血管性水腫 (HAE) 的治療格局正經歷著一場變革性的轉變，這主要得益於科學進步、病患偏好以及醫療服務模式的轉變。在分子層面，單株抗體和口服小分子藥物的創新，拓展了治療選擇，使其超越了傳統的血漿衍生療法，從而能夠透過新的機制抑制激肽釋放酶活性並選擇性地抑制緩激肽訊號傳導。技術進步也促成了重組 C1 抑制劑和皮下製劑的研發，降低了給藥的複雜性，支持居家治療，減少了預防性治療的門檻，並提高了治療的連續性。

評估近期美國關稅變化對 HAE 治療供應鏈、價格趨勢和策略採購方式的影響

美國2025年實施的新關稅對HAE的供應鏈、定價策略以及活性成分和成品生技藥品的跨境採購產生了多方面的影響。依賴國際原料採購和契約製造組織的製造商由於新增關稅和合規要求，其成本結構發生了變化，導致部分製造商重新調整供應商結構，並考慮垂直整合和增加近岸外包。低溫運輸物流，尤其是生物製藥，成本高昂且對前置作業時間要求嚴格，這加劇了關稅相關行政流程對營運的影響，並加重了進口商和經銷商的行政負擔。

綜合細分分析揭示了適應症、治療方法、給藥途徑、分銷管道和年齡層如何影響臨床和商業性決策。

關鍵的市場細分洞察凸顯了臨床創新、准入途徑和商業策略在適應症類型、藥物類別、給藥途徑、分銷管道和患者群體特徵方面的交匯點。從適應症角度來看，治療方案主要分為兩大類：急性治療和長期預防性治療。急性治療方案包括能夠快速抑制持續性緩激肽介導的腫脹的藥物，例如緩激肽受體拮抗劑、C1抑制劑和激肽釋放酶抑制劑。在C1抑制劑類別中，血漿來源產品和重組產品各自發揮不同的臨床和物流作用，而激肽釋放酶抑制劑則以單株抗體或口服小分子藥物的形式存在。長期預防治療同樣可分為以C1抑制劑為基礎的療法和激肽釋放酶抑制策略。每個子類別在作用持續時間、給藥頻率和監測要求方面各有優劣，血漿來源產品和重組產品，或單株抗體和小分子藥物，可根據不同的患者和醫療服務提供者的偏好進行選擇。

區域比較概覽，概述了監管、報銷和基礎設施方面的區域差異如何導致世界各地准入策略的差異

區域趨勢對遺傳性血管性水腫藥物的可及性、監管時間表和應用模式有顯著影響，因此，制定全球策略時必須採取細緻入微的視角。在美洲，完善的臨床試驗網路、成熟的專科藥房基礎設施以及支付方的深入了解，使得新型生物製藥和口服藥物能夠相對快速地引入市場，但報銷談判和事先核准流程可能會限制某些臨床環境下的藥物應用。製造商通常會優先考慮該地區的上市順序，並建立全面的患者支援體系，包括宅配服務和輸液培訓。

企業策略以及在製造、證據生成和患者服務方面的能力投資如何塑造遺傳性血管性水腫治療領域的競爭優勢

在HAE領域，企業策略體現了在維持現有生物製藥業務與投資下一代治療方法之間的平衡，這些療法有望帶來更便捷的使用體驗或差異化的作用機制。大型生物製藥公司憑藉其成熟的生產能力、與臨床醫生的良好關係以及分銷網路，在急診和預防性治療領域保持著穩固的地位。同時，新興生技公司則優先發展單株抗體、小分子藥物和重組蛋白，以獲得獨特的臨床優勢。成熟生產商與小規模創新企業之間的合作日益普遍，這使他們能夠加速臨床開發、擴大生產能力並分擔商業化責任。

製造商和相關人員可以採取哪些切實可行的策略行動來確保供應的穩定性，展現差異化價值，並改善HAE治療的病患療效？

為了在不斷發展的遺傳性血管性水腫（HAE）領域中獲取臨床和商業性價值，產業領導者應採取以韌性、差異化和以患者為中心為核心的綜合策略行動。首先，採購和製造地的多元化將降低受區域關稅波動和供應中斷的影響。將關鍵生物製藥的生產轉移到鄰近地區並確保多家原料藥供應商，將有助於提高生產的連續性。其次，為了擴大預防性治療的覆蓋範圍並提高患者依從性，企業應優先開發和商業化便於患者使用的製劑，例如皮下和口服給藥途徑，同時投資積累可靠的兒童證據，以支持擴大適應症。

調查方法概述：此方法整合臨床、監管、專家和供應鏈證據，為相關人員提供可操作的見解。

本分析整合了臨床文獻、監管申報文件、臨床試驗註冊資訊、專家訪談和供應鏈評估等證據，從多觀點呈現了遺傳性血管性水腫（HAE）的治療現狀。主要資訊來源包括對免疫學和過敏科臨床醫生、熟悉專科藥物分銷的藥房部門負責人以及熟悉罕見病報銷框架的支付方代表的結構化訪談。二級資訊來源包括關於病理學和療效比較的同行評審研究、監管核准文件以及已發布的罕見疾病管理指南，以綜合解讀臨床和政策訊號。

總結而言，協作創新、證據生成和運作韌性如何將治療進展轉化為患者照護的持續改善。

遺傳性血管性水腫 (HAE) 治療領域正處於一個轉折點，生物製藥創新、便捷的給藥方式以及不斷變化的支付方期望在此交匯，既帶來了新的機遇，也帶來了運營挑戰。臨床進展催生了更具針對性的預防和治療機制，而給藥方式的進步則改善了患者在醫療機構外獲得預防性護理的機會。同時，包括貿易政策調整、日益複雜的報銷流程以及地域覆蓋不均在內的外部壓力，正迫使生產商和醫療服務提供者在生產、定價和循證醫學證據收集方面採取更具戰略性的策略。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依適應症分類的遺傳性血管性水腫 (HAE) 治療市場

  • 急性治療
    • 緩激肽受體拮抗劑
    • C1抑制劑
    • C1抑制劑
      • 血漿衍生產品
      • 重組
    • 激肽釋放酶抑制劑
      • 單株抗體
      • 低分子化合物
  • 長期預防性治療
    • C1抑制劑
      • 血漿衍生產品
      • 重組
    • 激肽釋放酶抑制劑
      • 單株抗體
      • 低分子化合物

9. 遺傳性血管性水腫 (HAE) 治療藥物市場（依藥物類別分類）

  • 緩激肽受體拮抗劑
  • C1抑制劑
    • 血漿衍生
    • 重組
  • 激肽釋放酶抑制劑
    • 單株抗體
    • 低分子化合物

10. 遺傳性血管性水腫 (HAE) 治療藥物市場（依給藥途徑分類）

  • 靜脈注射
  • 口服
  • 皮下注射

第11章 遺傳性血管性水腫 (HAE) 治療市場（依分銷管道分類）

  • 醫院藥房
  • 零售藥房
  • 專科藥房

第12章：按患者年齡層分類的遺傳性血管性水腫 (HAE) 治療市場

  • 成人
  • 兒童

13. 各地區遺傳性血管性水腫 (HAE) 治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. 遺傳性血管性水腫 (HAE) 治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 遺傳性血管性水腫 (HAE) 治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國遺傳性血管性水腫（HAE）治療市場：

第17章：中國遺傳性血管性水腫（HAE）治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ADARx Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Astria Therapeutics, Inc.
  • Attune Pharmaceuticals, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • BioMarin Pharmaceutical Inc.
  • CSL Behring LLC
  • Grifols, SA
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Pharming Group NV
  • Pharvaris NV
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Industries Ltd.
Product Code: MRR-4F7A6D4FD87F

The Drugs for HAE Market was valued at USD 3.75 billion in 2025 and is projected to grow to USD 4.29 billion in 2026, with a CAGR of 12.24%, reaching USD 8.42 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.75 billion
Estimated Year [2026] USD 4.29 billion
Forecast Year [2032] USD 8.42 billion
CAGR (%) 12.24%

A concise clinical and therapeutic primer capturing hereditary angioedema pathophysiology, treatment categories, and evolving patient care priorities

Hereditary angioedema (HAE) is a rare, genetically mediated disorder characterized by episodic, nonpruritic swelling resulting from dysregulation of the kallikrein-kinin system and excess generation of the vasoactive peptide bradykinin. Clinically, HAE manifests with unpredictable attacks that can involve the extremities, face, airway, and gastrointestinal tract, posing both acute life-threat scenarios and chronic burdens on quality of life. The pathophysiology centers on either quantitative or functional deficiency of C1 esterase inhibitor or on specific defects in components that regulate kallikrein activity, which together drive bradykinin-mediated increased vascular permeability.

Therapeutic approaches divide into therapies for acute attack management and strategies for long-term prophylaxis. Acute interventions aim to resolve established swelling by interrupting kallikrein activity, blocking bradykinin receptors, or replacing deficient inhibitors. Prophylactic regimens seek to reduce attack frequency and severity through intermittent or continuous modulation of the same biological pathways. Over the past decade, treatment options have diversified to include plasma-derived and recombinant biologicals, monoclonal antibodies targeting kallikrein, and small-molecule oral agents, enabling more personalized regimens for adults and pediatric patients. As clinical practice evolves, emphasis increasingly rests on rapid access to effective acute care, safe and convenient prophylactic options, and integrated patient support to improve adherence and reduce emergency care utilization.

How scientific innovation, delivery model evolution, and payer emphasis on real world outcomes are reshaping therapeutic choices and care pathways for hereditary angioedema

The HAE treatment landscape is undergoing transformative shifts driven by scientific advances, patient preferences, and changes in care delivery. At the molecular level, innovations in monoclonal antibodies and orally available small molecules have expanded the therapeutic toolkit beyond traditional plasma-derived products, enabling new mechanisms to suppress kallikrein activity and blunt bradykinin signaling with greater selectivity. Technological refinement has also produced recombinant C1 inhibitors and subcutaneous formulations that reduce administration complexity and support at-home therapy, thereby lowering barriers to prophylaxis and improving continuity of care.

Concurrently, payers and providers are emphasizing value and real-world evidence, shifting contracting approaches toward outcomes-based arrangements and tighter formulary management. Telehealth integration and specialty pharmacy partnerships have facilitated remote initiation and ongoing monitoring, which is particularly important for rare disease populations who may be geographically dispersed. Trial design has adapted in parallel, with adaptive protocols and patient-reported outcome measures becoming more prominent to capture meaningful improvements in daily functioning. Taken together, these dynamics are reshaping clinical decision making, accelerating uptake of convenient and durable therapies, and prompting manufacturers to prioritize patient support services, real-world data collection, and differentiated delivery models to maintain competitive advantage.

Assessment of how recent United States tariff shifts have affected HAE therapeutic supply chains, pricing dynamics, and strategic sourcing approaches

The introduction of new tariff measures in the United States in 2025 created a spectrum of downstream implications for the HAE supply chain, pricing strategies, and cross-border procurement of active pharmaceutical ingredients and finished biologics. Manufacturers that rely on international raw material sourcing or contract manufacturing organizations found cost structures affected by additional duties and compliance requirements, prompting some to reassess supplier footprints and to explore greater vertical integration or nearshoring. For biologics, in particular, the cost and lead time sensitivities associated with cold-chain logistics magnified the operational impact of tariff-related administrative processes, increasing the administrative burden on importers and distributors.

Payers and contracting teams responded by scrutinizing procurement pathways and emphasizing domestic manufacturing where feasible to mitigate future policy volatility. Specialty pharmacies and hospital systems evaluated formulary implications and inventory strategies to ensure uninterrupted access for patients reliant on prophylactic regimens and on-demand therapies. Manufacturers adopted several mitigation tactics, including renegotiating supplier terms, diversifying API sources, and absorbing portions of tariff costs for flagship products to preserve clinical uptake and adherence. In parallel, regulatory engagement increased as stakeholders sought clarity on classification and duty codes for novel biologics and combination products to avoid inadvertent tariff exposure. These combined actions underscore the importance of supply chain resilience and policy foresight in sustaining access to HAE therapies amid shifting trade landscapes.

Integrated segmentation analysis revealing how indication, modality, administration route, distribution channel, and age demographics determine clinical and commercial decision making

Key segmentation insights illuminate where clinical innovation, access pathways, and commercial strategy intersect across indication types, drug classes, administration routes, distribution channels, and patient age groups. When the market is viewed through the lens of indication, therapeutic choices fall into two principal categories: acute treatment and long-term prophylaxis. Acute treatment options encompass agents that act rapidly to halt ongoing bradykinin-mediated swelling and include bradykinin receptor antagonists, C1 inhibitors, and kallikrein inhibitors; within the C1 inhibitors category, both plasma-derived and recombinant products play distinct clinical and logistical roles, while kallikrein inhibitors appear as monoclonal antibodies or as orally administered small molecules. Long-term prophylaxis similarly segments into C1 inhibitor-based approaches and kallikrein inhibition strategies, with each subcategory offering tradeoffs between durability of effect, administration frequency, and monitoring requirements, and with plasma-derived and recombinant formats or monoclonal and small-molecule chemistries catering to different patient and provider preferences.

Analyzing drug class segmentation reinforces the importance of modality on clinical decision making, as bradykinin receptor antagonists provide acute-phase pathway blockade whereas C1 inhibitors and kallikrein inhibitors offer both acute and prophylactic utility depending on formulation and dosing. Route of administration segmentation-spanning intravenous, oral, and subcutaneous delivery-clarifies the growing preference among patients and clinicians for convenient, self-administered modalities that reduce emergency department dependence and support adherence. Distribution channel considerations-hospital pharmacy, retail pharmacy, and specialty pharmacy-highlight variance in access pathways, with specialty pharmacies playing a pivotal role in patient education, reimbursement coordination, and home delivery, while hospital settings remain critical for acute care and intravenous administration. Finally, patient age group segmentation into adult and pediatric populations underscores distinct safety, dosing, and formulation needs, and the necessity of pediatric-specific evidence to support early intervention strategies and age-appropriate administration formats. Integrating these segmentation lenses enables a more granular approach to clinical trial design, commercial positioning, and patient support program development.

Comparative regional overview outlining how local regulatory, reimbursement, and infrastructure differences drive differentiated access strategies across global territories

Regional dynamics materially affect access, regulatory timelines, and adoption patterns for hereditary angioedema therapies, and a nuanced view is essential for global strategy. In the Americas, robust clinical trial networks, established specialty pharmacy infrastructure, and payer sophistication enable relatively rapid adoption of novel biologics and oral agents, although reimbursement negotiations and prior authorization processes can moderate uptake in certain care settings. Manufacturers often prioritize the region for launch sequencing and for building comprehensive patient support offerings that include home delivery and infusion training.

In Europe, Middle East & Africa, reimbursement variability across national systems shapes commercialization approaches; centralized approvals at supranational levels coexist with country-level health technology assessments that assess comparative effectiveness and budget impact. Procurement models and tendering practices in parts of the region can favor established suppliers or lower-cost alternatives, making evidence generation and pricing strategies critical. Regulatory harmonization efforts and greater engagement with regional patient advocacy groups are increasingly influential in improving access.

In the Asia-Pacific region, heterogeneity spans mature markets with advanced regulatory pathways and emerging markets with infrastructural constraints. Emerging economies place a high premium on affordability and local manufacturing partnerships, while advanced markets emphasize real-world evidence and alignment with regional clinical guidelines. Across the region, expanding clinical trial activity and growing specialist capacity present opportunities for scaled registries and post-marketing data collection to support long-term safety and comparative effectiveness assessments. Strategic regional differentiation in manufacturing, pricing, and evidence generation is therefore central to successful, equitable access.

How corporate strategies and capability investments in manufacturing, evidence generation, and patient services shape competitive advantage within hereditary angioedema therapeutics

Company strategies in the HAE space reflect a balance between sustaining legacy biologic franchises and investing in next-generation modalities that promise improved convenience and differentiated mechanisms of action. Large biopharmaceutical companies leverage established manufacturing capabilities, clinician relationships, and distribution networks to maintain presence in acute and prophylactic segments, while emerging biotechnology firms prioritize nimble development of monoclonal antibodies, small molecules, and recombinant proteins to capture niche clinical advantages. Partnerships between incumbent manufacturers and smaller innovators have become common, enabling accelerated clinical development, expanded manufacturing capacity, and shared commercialization responsibilities.

Across the industry, emphasis on differentiated patient services has become a competitive axis, with successful companies integrating education, adherence support, and reimbursement navigation into their go-to-market models. Investment in cold-chain logistics and biologics manufacturing scale is particularly important for companies supplying plasma-derived or recombinant C1 inhibitors, while developers of oral kallikrein inhibitors focus on establishing strong safety datasets and ease-of-use messaging. Corporate strategies also include targeted labeling expansions for pediatric populations and lifecycle management through novel formulations or delivery systems. Overall, capability in evidence generation, manufacturing resiliency, and payer engagement distinguishes market leaders from smaller entrants seeking to displace incumbents via clinical differentiation or cost advantages.

Practical strategic actions that manufacturers and stakeholders can implement to secure supply resilience, demonstrate differentiated value, and improve patient outcomes in HAE care

To capture clinical and commercial value in the evolving HAE landscape, industry leaders should adopt an integrated set of strategic actions focused on resilience, differentiation, and patient centricity. First, diversify sourcing and manufacturing footprints to reduce exposure to regional tariff shifts and supply interruptions; nearshoring critical biologics production and securing multiple API suppliers will improve continuity. Second, prioritize development and commercialization of patient-friendly formulations-such as subcutaneous or oral options-to expand prophylaxis uptake and improve adherence, while concurrently investing in robust pediatric evidence to support broader labeling.

Third, strengthen relationships with specialty pharmacies and expand digital patient support platforms that combine education, adherence reminders, and remote monitoring to reduce acute care reliance and demonstrate real-world value. Fourth, engage early and proactively with payers and health technology assessment bodies to align clinical trial endpoints with payer expectations and to explore outcomes-based contracting where appropriate. Fifth, invest in post-market safety and effectiveness studies and in registries that capture long-term outcomes across diverse patient populations, thereby reinforcing value propositions. Finally, incorporate scenario planning for trade and regulatory shifts into commercial forecasts and pricing strategies, ensuring agility in contracting and the ability to respond to policy changes without disrupting patient access. Together, these actions position companies to deliver clinically meaningful advances while safeguarding supply and commercial viability.

Methodology overview describing how clinical, regulatory, expert, and supply chain evidence were synthesized to generate actionable insights for stakeholders

This analysis synthesizes evidence from clinical literature, regulatory filings, trial registries, expert consultations, and supply chain assessments to provide a multidimensional view of the HAE therapeutic environment. Primary inputs included structured interviews with clinicians specializing in immunology and allergy, pharmacy leaders experienced in specialty product distribution, and payer representatives familiar with rare disease reimbursement frameworks. Secondary sources encompassed peer-reviewed studies on pathophysiology and comparative efficacy, regulatory approval documents, and published guidance on rare disease management to triangulate clinical and policy signals.

Supply chain and tariff impact assessments combined customs and trade classification analysis with stakeholder reporting from manufacturers and distributors to evaluate operational implications. Competitive and company capability insights were derived from public disclosures, pipeline tracking, and synthesis of partnership and licensing activity. Where relevant, patient advocacy perspectives were included to capture real-world access barriers and priorities. Throughout, methodological rigor was maintained via cross-validation of inputs, explicit documentation of assumptions, and transparent acknowledgment of data limitations, particularly where proprietary commercial terms or unpublished trial datasets were not accessible. This layered approach ensures balanced, actionable conclusions while recognizing the evolving nature of clinical evidence and policy environments.

Concluding perspective on how coordinated innovation, evidence generation, and operational resilience can convert therapeutic advances into sustained improvements in patient care

The hereditary angioedema therapeutic arena is at an inflection point where biologic innovation, convenient administration formats, and evolving payer expectations intersect to create new opportunities and operational challenges. Clinical progress has yielded more targeted mechanisms to prevent and treat attacks, and advancements in delivery have made prophylaxis more accessible outside institutional settings. At the same time, external pressures such as trade policy adjustments, reimbursement complexity, and regional heterogeneity in access require manufacturers and care providers to be more strategic about manufacturing, pricing, and evidence generation.

Looking ahead, stakeholders who align product development with patient preferences, invest in resilient supply chains, and build robust real-world evidence frameworks will be best positioned to deliver meaningful clinical benefits while sustaining commercial viability. Collaboration across manufacturers, specialty pharmacies, and payers to streamline access and to demonstrate outcomes in routine practice will be essential for translating therapeutic advances into better patient experiences and reduced acute care burden. In sum, coordinated, evidence-driven action is required to ensure that innovation in HAE therapy translates into durable improvements in patient health and health system efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drugs for HAE Market, by Indication Type

  • 8.1. Acute Treatment
    • 8.1.1. Bradykinin Receptor Antagonists
    • 8.1.2. C1 Inhibitors
    • 8.1.3. C1 Inhibitors
      • 8.1.3.1. Plasma Derived
      • 8.1.3.2. Recombinant
    • 8.1.4. Kallikrein Inhibitors
      • 8.1.4.1. Monoclonal
      • 8.1.4.2. Small Molecule
  • 8.2. Long Term Prophylaxis
    • 8.2.1. C1 Inhibitors
      • 8.2.1.1. Plasma Derived
      • 8.2.1.2. Recombinant
    • 8.2.2. Kallikrein Inhibitors
      • 8.2.2.1. Monoclonal
      • 8.2.2.2. Small Molecule

9. Drugs for HAE Market, by Drug Class

  • 9.1. Bradykinin Receptor Antagonists
  • 9.2. C1 Inhibitors
    • 9.2.1. Plasma Derived
    • 9.2.2. Recombinant
  • 9.3. Kallikrein Inhibitors
    • 9.3.1. Monoclonal
    • 9.3.2. Small Molecule

10. Drugs for HAE Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Drugs for HAE Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Retail Pharmacy
  • 11.3. Specialty Pharmacy

12. Drugs for HAE Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Pediatric

13. Drugs for HAE Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drugs for HAE Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drugs for HAE Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Drugs for HAE Market

17. China Drugs for HAE Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. ADARx Pharmaceuticals, Inc.
  • 18.6. Arrowhead Pharmaceuticals, Inc.
  • 18.7. Astria Therapeutics, Inc.
  • 18.8. Attune Pharmaceuticals, Inc.
  • 18.9. BioCryst Pharmaceuticals, Inc.
  • 18.10. BioMarin Pharmaceutical Inc.
  • 18.11. CSL Behring LLC
  • 18.12. Grifols, S.A.
  • 18.13. Intellia Therapeutics, Inc.
  • 18.14. Ionis Pharmaceuticals, Inc.
  • 18.15. KalVista Pharmaceuticals, Inc.
  • 18.16. Pharming Group N.V.
  • 18.17. Pharvaris N.V.
  • 18.18. Regeneron Pharmaceuticals, Inc.
  • 18.19. Sanofi S.A.
  • 18.20. Swedish Orphan Biovitrum AB
  • 18.21. Takeda Pharmaceutical Company Limited
  • 18.22. Teva Pharmaceuticals Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUGS FOR HAE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUGS FOR HAE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUGS FOR HAE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUGS FOR HAE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUGS FOR HAE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DRUGS FOR HAE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DRUGS FOR HAE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUGS FOR HAE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUGS FOR HAE MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUGS FOR HAE MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUGS FOR HAE MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUGS FOR HAE MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUGS FOR HAE MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUGS FOR HAE MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRUGS FOR HAE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUGS FOR HAE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRUGS FOR HAE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DRUGS FOR HAE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUGS FOR HAE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DRUGS FOR HAE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DRUGS FOR HAE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS DRUGS FOR HAE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL DRUGS FOR HAE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. GCC DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. GCC DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 239. GCC DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 240. GCC DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. GCC DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. GCC DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 247. GCC DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. GCC DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. GCC DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 278. G7 DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 279. G7 DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. G7 DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 281. G7 DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 282. G7 DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 284. G7 DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 285. G7 DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 286. G7 DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 287. G7 DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 288. G7 DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 289. G7 DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. G7 DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. G7 DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 292. NATO DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 293. NATO DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. NATO DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 295. NATO DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 296. NATO DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 297. NATO DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 298. NATO DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 299. NATO DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 300. NATO DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 301. NATO DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 302. NATO DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 303. NATO DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. NATO DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. NATO DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 306. GLOBAL DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES DRUGS FOR HAE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA DRUGS FOR HAE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)